Immunocore

News

Immunocore hires Lilly's Hotchkiss as chief commercial offic...

UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.

News

Immunocore and GSK pick third cancer immunotherapy target

Immunocore, one of UK biotech's brightest hopes, has selected a third target as part of its immuno-oncology partnership with GlaxoSmithKline.

News

Immunocore's T-cell therapy could provide HIV cure

Treatment promises cure by reactivating immune cells to kill latent HIV-infected cells.

R&D

Cityscape of Oxford City. Oxfordshire, England, UK

T-cell specialist Immunocore raises $320m in private finance

Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.

Cancer

Lilly and Immunocore collaborate on novel cancer therapies

Eli Lilly and Immunocore have agreed to collaborate on R&D into novel T-cell-based cancer therapies.

Immunocore hires Lilly's Hotchkiss as chief commercial offic...

Immunocore and GSK pick third cancer immunotherapy target

Immunocore's T-cell therapy could provide HIV cure

T-cell specialist Immunocore raises $320m in private finance

Lilly and Immunocore collaborate on novel cancer therapies

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Immunocore

Editor's Picks